AI Article Synopsis

  • Children with pituitary hormone deficiency face risks of secondary adrenal insufficiency (AI), and a glucagon stimulation test (GST) is evaluated as a diagnostic tool compared to standard tests.* -
  • A retrospective study of 120 pediatric patients assessed the GST's effectiveness in diagnosing AI but found it to have limited utility, particularly with lower sensitivity and specificity than the established low dose ACTH stimulation test (LDACTH).* -
  • The findings indicate that the GST should be used cautiously for diagnosing secondary AI, as it showed high sensitivity at a higher cut-off but low specificity, suggesting it's not the best diagnostic option.*

Article Abstract

Introduction: Children with a pituitary hormone deficiency are at risk for secondary adrenal insufficiency (AI). A stimulation test is usually performed for diagnosing AI, evaluating both the hypothalamic-pituitary-adrenal and growth hormone (GH)-IGF-1 axes. This single test is preferred by clinicians and is considerably more tolerable by patients. The objective of this study was to evaluate the glucagon stimulation test (GST), which is commonly used to assess both axes. Its diagnostic capability for GH deficiency is high and well accepted, however its utility for determining secondary AI has not been well established.

Methods: This retrospective study involved 120 patients under 18 years of age with short stature who had undergone both a GST and low dose ACTH stimulation test (LDACTH test). Twenty-six children who had more than 6 months elapsed between the two tests were excluded from the study. The study was conducted on patients of the Pediatric Endocrinology Department at Soroka University Hospital, a tertiary medical centre in Beer Sheva, Israel. Statistical analyses were carried out via IBM SPSS (v. 22), with a significance level determined at p < .05.

Results: Different cortisol cut-off values were assessed for GST and it was determined that the highest combined sensitivity and specificity yielded a cut-off point of 320 nmol/L (56% sensitivity and 83% specificity) while the currently accepted cut-off value (500 nmol/L) yielded 100% sensitivity and 6% specificity.

Conclusion: The results of this study show that GST is not an optimal tool for diagnosing secondary AI. Therefore, clinicians using this test should interpret its results with caution.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cen.14887DOI Listing

Publication Analysis

Top Keywords

stimulation test
16
glucagon stimulation
8
low dose
8
dose acth
8
test
7
comparison glucagon
4
stimulation
4
test low
4
acth test
4
test assessing
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!